According to a recent study by Future Market Insights, the global post-operative cataract surgery inflammation treatment market is poised for substantial growth over the next decade. The market, valued at US$ 4.56 billion in 2023, is projected to expand at a Compound Annual Growth Rate (CAGR) of 6.77%, reaching approximately US$ 8.78 billion by 2033.
This growth is largely driven by an increase in the accessibility of cortical necrosis therapeutics through retail pharmacies. With a growing number of retail pharmacies in developed nations, patients find it easier to access necessary medications post-surgery, contributing significantly to the market expansion.
Request A Sample Copy of This Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-16994
Market Growth Influencers:
- Increased Accessibility: The surge in retail pharmacies enhances patient access to post-surgery medications, bolstering market growth.
- Regulatory Approvals: The market is further supported by increased FDA approvals and clinical research surrounding cataract treatments. For example, in February 2018, EyePoint Pharmaceuticals received FDA approval for Dexycu, a single-dose intraocular suspension used at the conclusion of cataract surgery to manage postoperative inflammation. This approval is pivotal for addressing severe complications following cataract surgeries globally.
- Rising Incidence of Ocular Conditions: The increasing prevalence of conditions causing ocular pain, such as chemical and flash burns or infections like style and blepharitis, underscores the growing need for effective post-operative treatments.
Challenges to Market Growth:
- Shortage of Qualified Personnel: A notable challenge in the market is the lack of qualified personnel capable of administering the correct treatment protocols, which could restrain market growth.
- High Treatment Costs: The substantial costs associated with cataract treatment also pose a significant barrier to market expansion.
Methodology Details Just a Click Away: https://www.futuremarketinsights.com/request-report-methodology/rep-gb-16994
Key Takeaways from the Market Study:
- The market value in 2022 was US$ 4.045 Billion.
- The global post-operative cataract surgery inflammation treatment grew at a CAGR of 6.45% from 2018 to 2022.
- Increased approvals from FDA and more clinical research associated with cataracts are boosting the market growth.
- UK-based subsidiary of Japanese ophthalmology firm Santen Pharmaceutical has announced the launch of Ducressa.
- Allay Therapeutics, reported the first-ever clinical data showing non-opioid pain relief lasting two weeks after a single administration.
- North America is said to dominate the market share followed by Asia-Pacific.
Competitive Landscape:
Some of the prominent players in the post-operative cataract surgery inflammation drug treatment market are-
- Mallinckrodt Pharmaceuticals
- Salix Pharmaceuticals
- GlaxoSmithKline plc.
- Pfizer Inc.
- ASKA Pharmaceutical Co., Ltd.
- Bausch Health
- Johnson & Johnson Services, Inc.
- Janssen Global Services
- Takeda Pharmaceutical Company Limited
- Merck & Co., Inc.
Some of the important developments of the key players in the market are:
- In October 2022, Regeneron Pharmaceuticals, Inc. announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for EYLEA (aflibercept) Injection to treat Retinopathy of Prematurity (ROP) in preterm infants. This development helps the organization in developing its brand image in the ophthalmology market, among others.
- In May 2022, Reichert, Inc. has launched its redesigned refractometers & analytical instruments website with a vastly improved user experience.
Direct Purchase of this Report: https://www.futuremarketinsights.com/checkout/16994
Key Segments Profiled in the Post-Operative Cataract Surgery Inflammation Drug Treatment Market:
By Drug Class:
- Bromfenac
- Indomethacin
- Dicofenac
- Flurbiprofen
- Nepafenac
By Route of Administration:
- Oral
- Injectable
By Distribution Channel:
- Hospital pharmacy
- Online Pharmacy
- Retail pharmacy
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube